Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2169-2182

  Aziz, Athar ^a,b   Baxter, E Joanna ^a,b,c   Edwards, Carol ^a   Cheong, Clara Yujing ^d   Ito, Mitsuteru ^a   Bench, Anthony ^c   Kelley, Rebecca ^a,b   Silber, Yvonne ^a,b   Beer, Philip A ^a,b,c   Chng, Keefe ^d   Renfree, Marilyn B ^e   McEwen, Kirsten ^a   Gray, Dionne ^a   Nangalia, Jyoti ^a,b,c   Mufti, Ghulam J ^f   Hellstrom Lindberg, Eva ^g   Kiladjian, Jean Jacques ^h,i   McMullin, Mary Frances ^j   Campbell, Peter J ^b,c,k   Ferguson Smith, Anne C ^a   Green, Anthony R ^a,b,c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d AGENCY FOR SCIENCE   (Singapore)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; L3MBTL1 PROTEIN; MYC PROTEIN; PROTEIN; PROTEIN SWI; SGK2 PROTEIN; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CHROMATIN STRUCTURE; CHROMOSOME 20Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOCUS; GENE SILENCING; GENOME IMPRINTING; HEMATOPOIESIS; HUMAN; LOSS OF FUNCTION MUTATION; MALE; MEGAKARYOPOIESIS; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ALLELES; ANIMALS; CELL LINEAGE; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENOMIC IMPRINTING; HETEROZYGOTE; HUMANS; IMMEDIATE-EARLY PROTEINS; MACACA; MACROPODIDAE; MALE; MODELS, GENETIC; MULTIGENE FAMILY; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84877153495     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66113     Document Type: Article

References (68)

1. Beroukhim R, et al. The landscape of somatic copynumber alteration across human cancers. Nature. 2010;463(7283):899-905.
2. Bignell GR, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463(7283):893-898.
3. Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
4. James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
5. Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
6. Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential throm-bocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
7. Ebert BL, et al. Identification of RPS14 as a 5qsyndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
8. Liu TX, et al. Chromosome 5q deletion and epi-genetic suppression of the gene encoding alphacatenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13(1):78-83.
9. Starczynowski DT, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16(1):49-58.
10. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myelo-proliferative disorders. Br J Haematol. 1996; 95(2):219-226.
11. Bench AJ, et al. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics. 1998;49(3):351-362.
12. Bench AJ, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene. 2000;19(34):3902-3913.
13. Bench AJ, et al. Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Br J Haematol. 2004;127(5):509-518.
14. Boccuni P, MacGrogan D, Scandura JM, Nimer SD. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem. 2003;278(17):15412-15420.
15. Sims JK, Rice JC. PR-Set7 establishes a repressive trans-tail histone code that regulates differentiation. Mol Cell Biol. 2008;28(14):4459-4468.
16. Trojer P, Li G, Sims RJ. L3MBTL1, a histonemethylation-dependent chromatin lock. Cell. 2007;129(5):915-928.
17. Gateff E, Loffler T, Wismar J. A temperaturesensitive brain tumor suppressor mutation of Drosophila melanogaster: developmental studies and molecular localization of the gene. Mech Dev. 1993;41(1):15-31.
18. Wismar J, et al. The Drosophila melanogaster tumor suppressor gene lethal(3)malignant brain tumor encodes a proline-rich protein with a novel zinc finger. Mech Dev. 1995;53(1):141-154.
19. Kim J, et al. Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep. 2006;7(4):397-403.
20. Li H, et al. Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. Mol Cell. 2007;28(4):677-691.
21. Trojer P, Reinberg D. Beyond histone methyl-lysine binding: how malignant brain tumor (MBT) protein L3MBTL1 impacts chromatin structure. Cell Cycle. 2008;7(5):578-585.
22. Gurvich N, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A. 2010;107(52):22552-22557.
23. MacGrogan D, et al. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes Cancer. 2004;41(3):203-213.
24. Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci U S A. 2004;101(19):7341-7346.
25. Li J, et al. L3mbtl, the mouse orthologue of the imprinted L3MBTL, displays a complex pattern of alternative splicing and escapes genomic imprinting. Genomics. 2005;86(4):489-494.
26. Coan PM, Burton GJ, Ferguson-Smith AC. Imprinted genes in the placenta - a review. Placenta. 2005;26(suppl A):S10-S20.
27. Charalambous M, da Rocha ST, Ferguson-Smith AC. Genomic imprinting, growth control and the allocation of nutritional resources: consequences for postnatal life. Curr Opin Endocrinol Diabetes Obes. 2007;14(1):3-12.
28. Anand S, et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood. 2011;118(1):177-181.
29. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143-153.
30. Niemitz EL, et al. Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome. Am J Hum Genet. 2004;75(5):844-849.
31. Jinno Y, et al. Mosaic and polymorphic imprinting of the WT1 gene in humans. Nat Genet. 1994;6(3):305-309.
32. Killian JK, et al. Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations. Hum Mutat. 2001;18(1):25-31.
33. Nishiwaki K, Niikawa N, Ishikawa M. Polymorphic and tissue-specific imprinting of the human Wilms tumor gene, WT1. Jpn J Hum Genet. 1997; 42(1):205-211.
34. Piras G, et al. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol. 2000;20(9):3308-3315.
35. Plass C, et al. Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M. Nat Genet. 1996;14(1):106-109.
36. Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17(12):2474-2486.
37. Tsai CE, Lin SP, Ito M, Takagi N, Takada S, Ferguson-Smith AC. Genomic imprinting contributes to thyroid hormone metabolism in the mouse embryo. Curr Biol. 2002;12(14):1221-1226.
38. Yevtodiyenko A, Carr MS, Patel N, Schmidt JV. Analysis of candidate imprinted genes linked to Dlk1-Gtl2 using a congenic mouse line. Mamm Genome. 2002;13(11):633-638.
39. Messerschmidt DM, de Vries W, Ito M, Solter D, Ferguson-Smith A, Knowles BB. Trim28 is required for epigenetic stability during mouse oocyte to embryo transition. Science. 2012;335(6075):1499-1502.
40. Evans HK, Wylie AA, Murphy SK, Jirtle RL. The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2. Genomics. 2001;77(1-2):99-104.
41. Dupont S, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013-1021.
42. Jacob B, et al. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood. 2009;115(8):1610-1620.
43. Kvinlaug BT, et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011; 71(12):4117-4129.
44. Li J, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538.
45. Motoda L, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007;25(12):2976-2986.
46. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 1997;90(1):64-69.
47. Schemionek M, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010;115(16):3185-3195.
48. Mizuno H, Nishida E. The ERK MAP kinase pathway mediates induction of SGK (serum- and glucocorticoid-inducible kinase) by growth factors. Genes Cells. 2001;6(3):261-268.
49. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001;21(3):952-965.
50. Chi TH, et al. Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity. 2003;19(2):169-182.
51. Trotter KW, Archer TK. Nuclear receptors and chromatin remodeling machinery. Mol Cell Endocrinol. 2007;265-266:162-167.
52. Sif S, Stukenberg PT, Kirschner MW, Kingston RE. Mitotic inactivation of a human SWI/SNF chromatin remodeling complex. Genes Dev. 1998;12(18):2842-2851.
53. Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244(4901):217-221.
54. Bookstein R, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A. 1990;87(19):7762-7766.
55. Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8(1):27-32.
56. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. Widespread monoallelic expression on human autosomes. Science. 2007;318(5853):1136-1140.
57. Qin J, et al. Chromatin protein L3MBTL1 is dispensable for development and tumor suppression in mice. J Biol Chem. 2010;285(36):27767-27775.
58. Asimakopoulos FA, Gilbert JG, Aldred MA, Pearson TC, Green AR. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood. 1996;88(7):2690-2698.
59. Barlow JL, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med. 2009;16(1):59-66.
60. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726-734.
61. Schaub FX, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009;113(9):2022-2027.
62. Wajapeyee N, et al. Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins. Blood. 2010;115(24):5057-5060.
63. Perna F, et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q-polycythemia vera. Blood. 2010;116(15):2812-2821.
64. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene. 2009; 28(14):1653-1668.
65. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481-492.
66. Rui L, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010; 18(6):590-605.
67. Jayapal SR, Lee KL, Ji P, Kaldis P, Lim B, Lodish HF. Down-regulation of Myc is essential for terminal erythroid maturation. J Biol Chem. 2010;285(51):40252-40265.
68. Macaulay IC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109(8):3260-3269.